Testosterone Enanthate Cost in Connecticut (2026): Cash, Insurance, and Compounded Pricing

Testosterone enanthate is a generic injectable androgen ester, FDA-approved (as Delatestryl, NDA 009165, and multiple generic equivalents) for testosterone replacement in men with clinically and biochemically confirmed hypogonadism. It is a Schedule III controlled substance under federal law and is dosed by intramuscular injection, commonly on a weekly or every-other-week schedule set by a prescriber. It should not be confused with testosterone cypionate (a closely related but separate ester), testosterone undecanoate (Aveed, a long-acting product with its own dosing schedule and cost profile), or compounded testosterone preparations made outside the standard FDA-approved supply chain.

The drug itself is inexpensive relative to most other testosterone delivery systems. That is the easy part. The harder and more useful question for a Connecticut patient is not "what does the vial cost," but which of several cost pathways applies to you: cash purchase, commercial insurance with prior authorization, Connecticut Medicaid (HUSKY Health) with prior authorization, or a compounded 503A product. Which pathway you land in, and whether your labs and diagnosis satisfy that pathway's documentation requirements, matters more to your final bill than the sticker price of the medication.

The core answer: Testosterone enanthate's ingredient cost is not the main driver of what a Connecticut patient pays for it. FDA labeling confirms the drug is approved for male hypogonadism and classified as a Schedule III controlled substance, and Connecticut permits telehealth prescribing of controlled substances where a valid provider-patient relationship exists. What determines the final price is whether a patient's diagnosis and lab documentation clear a specific payer's prior-authorization requirement, a rule that varies by plan, changes over time, and cannot be assumed from a general reference article. Any specific dollar figure for Connecticut should be confirmed directly with the dispensing pharmacy or insurer on the day of fill, not assumed from a published range.

What this article can and cannot tell you about price

No Connecticut-specific pricing database, insurer bulletin, or state Medicaid fee schedule was available in the source material used to build this page. The figures that circulate for testosterone enanthate cash prices, compounding pharmacy rates, and telehealth subscription fees come from the retail pharmacy and telehealth market generally, and they shift by pharmacy chain, vial size, discount card, and time of year. Rather than state a single average price for Connecticut as though it were fixed, this article separates what is durable (FDA status, guideline-based clinical criteria) from what a reader must verify at the point of care (an exact dollar figure, a specific insurer's prior-authorization checklist, a specific pharmacy's cash price).

Cash-pay pricing: general pattern, not a confirmed Connecticut figure

Generic injectable testosterone esters, including enanthate and cypionate, are among the least expensive testosterone delivery forms on the U.S. market because they are off-patent and produced by multiple manufacturers. Retail cash prices for a single-dose or short-supply vial commonly fall in a low double-digit to low triple-digit dollar range depending on concentration, vial size, and whether a pharmacy discount card is used. Manufacturer list price (wholesale acquisition cost before markups, rebates, or discounts) is typically higher than what most cash-pay patients end up paying at the register, since discount cards and pharmacy competition compress the retail price.

None of the specific dollar figures sometimes quoted for Connecticut pharmacies, or for named chains within the state, could be verified against a primary source for this draft. Before relying on any number, call the dispensing pharmacy or check a current pharmacy discount tool for the exact NDC, vial size, and concentration your prescription specifies. A 1 mL single-dose vial and a 5 mL or 10 mL multi-dose vial of the same concentration will have very different per-week costs, and that difference is usually larger than any city-to-city variation within Connecticut.

Should you use insurance, and what will it require?

Commercial insurers generally cover generic testosterone enanthate when a patient has a documented diagnosis of male hypogonadism supported by repeated low morning serum testosterone measurements and consistent symptoms. This aligns with the Endocrine Society's 2018 clinical practice guideline, which recommends testosterone therapy for men with symptomatic testosterone deficiency confirmed by reliable laboratory assays and recommends against starting therapy on a single low value or in asymptomatic men.3

Specific prior-authorization criteria (which lab thresholds a given plan accepts, whether a second confirmatory test is required, whether an LH/FSH level must accompany the request) vary by insurer and by plan year, and they change without much public notice. A general framework that most Connecticut commercial plans are likely to follow, in keeping with the Endocrine Society's guideline, is two morning total testosterone measurements below the reference threshold plus documented symptoms consistent with androgen deficiency. The exact numeric cutoff, and any additional documentation a specific plan requires, should be confirmed with that plan's pharmacy benefit manager or the prescriber's prior-authorization team before assuming coverage or estimating a copay. Step therapy (a requirement to try a topical gel first) is uncommon for an already inexpensive injectable but does appear on some formularies; a formulary exception request can cite injection preference, adherence history, or the risk of topical-to-partner transference that is addressed in testosterone product labeling.1

Connecticut Medicaid (HUSKY Health): covered, with prior authorization

Connecticut Medicaid covers testosterone enanthate for male hypogonadism, and prior authorization is required. As with commercial plans, the specific documentation threshold, turnaround time, and appeal process are administrative details that change and should be confirmed directly with HUSKY Health or the Connecticut Department of Social Services rather than assumed from a general article. If a request is denied, Medicaid beneficiaries generally retain a right to appeal; ask the plan or DSS directly for the current appeal window and process, since exact timelines are not something this article can state reliably without a primary source.

Body-composition outcome data sometimes cited to support these appeals come from an observational meta-analysis (not a randomized trial) published in the Journal of Endocrinology Investigation, which found improvements in fat mass and lean mass associated with testosterone supplementation across pooled observational studies.4 This is useful supporting evidence for a letter of medical necessity, but it is observational evidence, not trial-level proof of an individual patient's expected response, and it should be presented to a payer as such.

Is compounded testosterone enanthate a reasonable option?

Compounded testosterone enanthate can be legally dispensed in Connecticut through a state-licensed 503A compounding pharmacy with a valid, patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits this kind of compounding, and the FDA's own guidance on compounding explains the distinction between 503A pharmacy compounding and FDA-approved manufactured drugs.5

The tradeoff is real and worth stating plainly: compounded products do not go through FDA's approval process for safety, efficacy, or manufacturing consistency the way Delatestryl and its generic equivalents do. The Endocrine Society's guideline recommends FDA-approved formulations when one is available and clinically appropriate, reserving compounding for situations with a specific clinical reason, such as an allergy to a carrier oil used in the commercial product or a need for a non-standard concentration.3 If you use a compounded product, confirm that the pharmacy holds a current Connecticut compounding license, follows USP 795/797/800 sterile and non-sterile compounding standards as applicable, and can provide a certificate of analysis for the batch dispensed. Price claims for compounded testosterone enanthate vary by pharmacy and by whether the patient prepays for a multi-month supply; get a written quote before committing.

Is telehealth prescribing legitimate in Connecticut?

Yes, in general. Connecticut law permits telehealth prescribing of controlled substances, including Schedule III medications such as testosterone enanthate, when a valid provider-patient relationship exists and the prescriber holds an active Connecticut license (or equivalent interstate authority) and DEA registration. The exact statutory framework and any conditions attached to controlled-substance telehealth prescribing have evolved since the COVID-19 public health emergency and should be confirmed against current Connecticut Department of Consumer Protection guidance rather than a fixed citation, since this is the kind of regulatory detail that changes over time.

Whatever platform or clinician you use, monitoring should not be skipped because the visit was virtual. The American Urological Association's guideline on testosterone deficiency recommends checking hematocrit, PSA, and testosterone levels at three to six months after starting therapy and at least annually thereafter, and this standard applies regardless of whether the prescription originated in person or by telehealth.6

How does enanthate compare in cost to other TRT options?

As a general market pattern (not a Connecticut-specific price table), short-acting injectable esters like testosterone enanthate and testosterone cypionate tend to be the least expensive route of testosterone delivery because both are older, off-patent, and produced by several manufacturers. Longer-acting injectables such as testosterone undecanoate (Aveed), and non-injectable routes such as transdermal gels, patches, nasal gel, and subcutaneous pellets, are generally priced higher per month, both because of formulation cost and because some require an in-office procedure (pellet insertion) or brand-only availability. Exact current prices for any of these products should be obtained from a pharmacy or benefits manager rather than assumed, since manufacturer pricing and discount program availability shift over time.

Pharmacokinetically, enanthate and cypionate are considered broadly interchangeable esters with similar half-lives measured in days rather than weeks, a comparison discussed in historical reviews of testosterone ester development.8 That similarity is one reason insurers rarely require step therapy between the two injectable esters, even though they may require a trial of a topical product before either injectable is approved.

What the clinical trial evidence actually supports, and its limit

The Testosterone Trials (T-Trials), a coordinated set of placebo-controlled studies in men aged 65 and older with confirmed low testosterone, found that treatment raised serum testosterone into the mid-normal range and produced improvements in sexual function, physical function, and mood over 12 months.2 This is a genuinely important piece of trial evidence for testosterone therapy generally, and it is often cited to justify insurance coverage of the drug class.

It has a boundary worth stating clearly: the T-Trials tested transdermal testosterone gel, not the injectable enanthate ester. The trial supports the broader claim that correcting confirmed hypogonadism improves several patient-reported outcomes; it does not itself demonstrate that the injectable enanthate formulation produces an identical magnitude of benefit, since route of administration affects the pattern of serum testosterone levels (peaks and troughs with injections versus steadier levels with daily gel). Extrapolating gel-trial results to injectable therapy is a reasonable clinical inference shared by guideline authors, but it is an inference, not a direct trial finding, and a careful reader should not treat the two as interchangeable evidence.

Lab monitoring: a recurring cost beyond the medication

Testosterone therapy requires monitoring, and this is a real, recurring line item beyond the drug's price. FDA labeling for testosterone enanthate identifies polycythemia (excess red blood cell production) as a labeled risk and recommends hematocrit monitoring at baseline and periodically during treatment.1 The AUA guideline specifies checking testosterone, hematocrit, and PSA at three to six months after starting and at least annually thereafter.6 Typical baseline labs before starting therapy include total and free testosterone (usually on two separate mornings), LH, FSH, a complete blood count, a metabolic panel, a lipid panel, and PSA in men over 40. Exact lab costs depend on the lab network, insurance status, and whether a discount cash-pay lab option is used locally; get a specific quote from the ordering lab rather than assuming a fixed figure.

Who should not start testosterone therapy, and when to seek urgent care

Testosterone therapy is generally contraindicated in men with known or suspected prostate cancer, known or suspected male breast cancer, and untreated severe polycythemia, and it requires caution in men with significant untreated obstructive sleep apnea or poorly controlled heart failure. The Endocrine Society guideline also advises against starting testosterone in men who wish to preserve fertility in the near term, since exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and can reduce sperm production.3 Off-label alternatives such as clomiphene citrate or enclomiphene are sometimes used instead when fertility preservation is a priority; these are off-label uses and should be discussed directly with a prescriber, not started based on this article.

Seek urgent medical care rather than waiting for a routine follow-up if you develop chest pain, sudden shortness of breath, one-sided weakness, slurred speech, severe headache with vision changes, or a cough and chest tightness starting immediately after an injection. These can reflect cardiovascular events, hyperviscosity from elevated hematocrit, or an acute reaction to an oil-based injectable, and none of them should be managed by waiting for a scheduled lab draw.

What is established, what is plausible, and what is not established

Established: testosterone enanthate is FDA-approved for male hypogonadism, is a Schedule III controlled substance, and carries a labeled requirement for hematocrit monitoring. Trial evidence supports meaningful symptomatic benefit from correcting confirmed hypogonadism, though that trial evidence was generated with a gel formulation rather than the injectable ester. Compounded 503A testosterone enanthate is legal in Connecticut under federal and state compounding law when dispensed by a licensed pharmacy against a valid prescription.

Plausible but unproven at the level of a confirmed statistic: that injectable enanthate produces benefits identical in size to the gel formulation tested in the T-Trials; that any single dollar figure represents "the" Connecticut price for cash-pay testosterone enanthate across pharmacies and time.

Not established by the source material available for this article: specific insurer-by-insurer prior-authorization lab thresholds in Connecticut, a specific Connecticut Medicaid prior-authorization turnaround time, specific income eligibility figures for Connecticut Medicaid categories, and specific per-pharmacy price averages for Connecticut cities. These require direct verification with the payer, pharmacy, or state agency at the time you need the answer.

Verification checklist: stable facts versus facts you must re-check

Use this before you rely on any number or rule from this page, or from any other general reference page on this topic.

Stable facts (federal regulatory or clinical-guideline based, unlikely to change month to month):

• Testosterone enanthate is FDA-approved for male hypogonadism and is a Schedule III controlled substance under federal law.
• FDA labeling calls for hematocrit monitoring due to polycythemia risk.
• The AUA guideline recommends testosterone, hematocrit, and PSA monitoring at three to six months after starting therapy and annually thereafter.
• The Endocrine Society guideline recommends confirming hypogonadism with repeated low morning testosterone plus symptoms before starting treatment, and advises against starting therapy in men prioritizing near-term fertility.
• Compounded 503A testosterone enanthate is legally permitted nationwide, including in Connecticut, under FDCA Section 503A when dispensed by a licensed pharmacy against a valid patient-specific prescription.

Volatile facts (confirm on the day you need them, not from this or any general article):

• The exact cash price for your specific vial size, concentration, and pharmacy.
• Your specific insurance plan's prior-authorization lab thresholds and required documentation.
• Whether your plan requires step therapy with a topical product first.
• Connecticut Medicaid's current prior-authorization turnaround time and appeal window.
• Current HUSKY Health income eligibility thresholds (these track the federal poverty level, which is updated annually).
• A specific telehealth platform's monthly service fee and whether medication cost is bundled.
• A specific compounding pharmacy's current license status and batch certificate of analysis.

Before you pay or file an appeal, ask:

1. What is today's cash price for this exact NDC, vial size, and concentration, with and without a discount card?
2. What lab values and symptom documentation does my specific plan require for approval, in writing?
3. Is my prescribing pharmacy a state-licensed 503A compounder if I am filling a compounded product, and can they provide a current certificate of analysis?
4. If telehealth-prescribed, does the platform bundle medication and lab costs, or bill them separately?
5. What is my plan's or Medicaid's current appeal process and deadline if a request is denied?